AR059174A1 - Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas) - Google Patents

Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)

Info

Publication number
AR059174A1
AR059174A1 ARP070100300A ARP070100300A AR059174A1 AR 059174 A1 AR059174 A1 AR 059174A1 AR P070100300 A ARP070100300 A AR P070100300A AR P070100300 A ARP070100300 A AR P070100300A AR 059174 A1 AR059174 A1 AR 059174A1
Authority
AR
Argentina
Prior art keywords
film
obleas
oral cavity
pharmaceutical forms
gestagens
Prior art date
Application number
ARP070100300A
Other languages
English (en)
Inventor
Hans-Peter Podhaisky
Stefan Bracht
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR059174A1 publication Critical patent/AR059174A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Sistema en forma de película de aplicacion bucal transmucosa que contiene: una hormona esteroide del grupo de los androgenos, los gestágenos y los estrogenos; el 30-70% en peso de una ciclodextrina o de un derivado de ciclodextrina; un formador de película que se descompone en medio acuoso. Procedimiento para preparar dicho sistema y uso en la prevencion y terapia de enfermedades por déficit de androgenos, gestágenos y/o estrogenos.
ARP070100300A 2006-01-24 2007-01-24 Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas) AR059174A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006003512A DE102006003512A1 (de) 2006-01-24 2006-01-24 Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen

Publications (1)

Publication Number Publication Date
AR059174A1 true AR059174A1 (es) 2008-03-12

Family

ID=37930392

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100300A AR059174A1 (es) 2006-01-24 2007-01-24 Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)

Country Status (13)

Country Link
US (1) US20070292479A1 (es)
EP (1) EP1978927A1 (es)
JP (1) JP2009523837A (es)
KR (1) KR20080091156A (es)
CN (1) CN101374500A (es)
AR (1) AR059174A1 (es)
CA (1) CA2637300A1 (es)
DE (1) DE102006003512A1 (es)
DO (1) DOP2007000017A (es)
PE (1) PE20071244A1 (es)
TW (1) TW200808382A (es)
UY (1) UY30109A1 (es)
WO (1) WO2007085498A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
MX2010008940A (es) * 2008-02-13 2010-10-05 Bayer Schering Pharma Ag Sistemas de administracion de drogas que contienen estradiol.
US20110052699A1 (en) * 2008-02-13 2011-03-03 Adrian Funke Drug delivery system with stabilising effect
DE102008023345B4 (de) * 2008-05-13 2014-12-04 Lts Lohmann Therapie-Systeme Ag Filmförmige Zubereitung mit öligen Substanzen zur oralen Verabreichung
US9265779B2 (en) 2008-05-13 2016-02-23 Lts Lohmann Therapie-Systeme Ag Method of using a film-shaped preparation comprising oily substances for oral administration
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
CA2744127A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
UY32836A (es) * 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
CA2771358A1 (en) 2009-08-19 2011-02-24 Sascha General Drug delivery systems (wafer) for pediatric use
CN101919803A (zh) * 2010-07-16 2010-12-22 钟术光 一种控释制剂
CN101985044B (zh) * 2010-07-16 2013-10-23 钟术光 一种掩味的药物涂层组合物
IT1401354B1 (it) * 2010-08-02 2013-07-18 Quaglia Sistemi per il rilascio controllato a base di polimeri bioadesivi loro processo di produzione e impieghi clinici
CN102440979A (zh) * 2010-09-30 2012-05-09 迪特克(济源)绿色生物科技有限公司 一种纤维素衍生物复合膜及其制备方法
US20140271867A1 (en) * 2013-03-15 2014-09-18 Monosol Rx, Llc Film delivery system for active ingredients
US20130115266A1 (en) * 2011-11-04 2013-05-09 Bestsweet, Inc. Edible wafer-type product for delivery of nutraceuticals and pharmaceuticals
AU2013344654B2 (en) * 2012-11-14 2017-06-22 Abon Pharmaceuticals, Llc Oral transmucosal drug delivery system
WO2014144366A1 (en) * 2013-03-15 2014-09-18 Monosol Rx, Llc. Steroid hormone delivery systems and methods of preparing the same
KR20170132319A (ko) * 2015-04-03 2017-12-01 산텐 세이야꾸 가부시키가이샤 난드롤론 또는 그 에스테르, 메테놀론 또는 그 에스테르를 유효 성분으로 하는 드라이아이 치료제
EP3423045A4 (en) * 2016-03-02 2020-01-01 Kenox Pharmaceuticals Inc PHARMACEUTICAL COMPOSITIONS FOR ON-DEMAND ANTICOAGULANT THERAPY
RU2699808C2 (ru) * 2017-12-05 2019-09-11 Общество с ограниченной ответственностью "Эндокринные технологии" Биоразлагаемая система трансмукозальной доставки дротаверина
DE102018002066A1 (de) 2018-03-14 2019-09-19 Irina Gentsinger Orale filmförmige Darreichungsform
RU2729659C1 (ru) * 2019-05-29 2020-08-11 Общество с ограниченной ответственностью "Эндокринные технологии" Лекарственная форма для высвобождения дротаверина в полости рта
CN116077416A (zh) * 2021-11-05 2023-05-09 深圳埃格林医药有限公司 一种包含孕激素的新型口服制剂及制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6284262B1 (en) * 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
CZ300551B6 (cs) * 1999-03-31 2009-06-17 Janssen Pharmaceutica N. V. Predželatinovaný škrob v rízene se uvolnující formulaci
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
WO2002045701A2 (en) * 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
WO2003011259A1 (en) * 2001-07-30 2003-02-13 Wm. Wrigley Jr. Company Improved edible film formulations containing maltodextrin
US20040115137A1 (en) * 2002-12-17 2004-06-17 Verrall Andrew P. Water-soluble film for oral administration
WO2005011618A2 (en) * 2003-07-31 2005-02-10 Ivax Corporation Methods for the treatment of male and female sexual dysfunction
US20050239747A1 (en) * 2004-04-21 2005-10-27 Pharmaceutical Industry Technology And Development Center Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods

Also Published As

Publication number Publication date
JP2009523837A (ja) 2009-06-25
CA2637300A1 (en) 2007-08-02
CN101374500A (zh) 2009-02-25
KR20080091156A (ko) 2008-10-09
US20070292479A1 (en) 2007-12-20
TW200808382A (en) 2008-02-16
WO2007085498A1 (de) 2007-08-02
PE20071244A1 (es) 2008-02-24
DOP2007000017A (es) 2007-09-15
DE102006003512A1 (de) 2007-08-02
UY30109A1 (es) 2007-08-31
EP1978927A1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
AR059174A1 (es) Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)
PE20070329A1 (es) Composiciones con estrogenos y metodos terapeuticos para su uso
CY1118496T1 (el) Φαρμακεyτικες συνθεσεις
CL2009002187A1 (es) Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06).
AR032204A1 (es) Complejos de inclusion de ciclodextrina-drospirenona
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
AR080912A1 (es) Formas de dosificacion solidas orales con dosis muy bajas para la hrt
CR10975A (es) Formulaciones para el tratamiento del cancer
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
NO20082460L (no) Fremgangsmater for a redusere alkoholindusert dosedumping for opioid-vedvarende frigivelse orale doseringsformer
CR9468A (es) Oblea que contiene hormonas esteroides
GT200900090A (es) Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
CO7160008A2 (es) Derivados de estra- 1,3,5(10),16- tetraeno 3-sustituidos, métodos para su preparación, prepara-ciones farmaceúticas que los contienen, así como su uso para la preparación de medicamentos
CL2012001596A1 (es) Compuestos derivados de triazolopiridina, pirazolopirimidina, triazolopirimidina o pirazolopiridina, modulador alosterico positivo del receptor mglur5; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la esquizofrenia o de una enfermedad cognitiva.
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
CL2019000174A1 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d.

Legal Events

Date Code Title Description
FB Suspension of granting procedure